MedTrace Logo

CH1701 for Prevention and Treatment of Radiation Burns

NCT04386343 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-08-24

No results posted yet for this study

Summary

A combined Phase I\&II, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety for prevention and treatment of radiation therapy burn of CH1701

Conditions

Interventions

DRUG

CH1701 for prevention and treatment of radiation burns.

Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.

DRUG

Safety assessment of CH1701

Safety assessment of CH1701 after 14 days of use on volunteers

DRUG

Placebos

The placebo was used on patients as a control for the doses of CH1701

Sponsors & Collaborators

  • Vietnam National Cancer Hospital

    collaborator INDIV

  • Vietlife Healthcare Corporation

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-05
Primary Completion
2020-12-31
Completion
2020-12-01

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04386343 on ClinicalTrials.gov